Navigation path

Pharmaceuticals - Community Register


Community register of orphan medicinal products


Product information


EU orphan designation number: EU/3/12/1050   
Active ingredient: [2-Cyano-3-cyclopropyl-3-hydroxy-N-(3-methyl-4-trifluoromethylphenyl)prop-2-enamide]
Indication: Treatment of traumatic spinal cord injury
Sponsor: Algiax Pharmaceuticals GmbH
Max-Planck-Straße 15a, 40699 Erkrath, Deutschland

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
12/10/2012 Orphan designation EMA/OD/088/12 (2012)7227 of 10/10/2012